CD34 and Schnyder corneal dystrophy: CRISPR-Cas9-genome editing has been extensively applied for KLF-1 disruption in erythroid cell lines, normal- and SCD patient-derived CD34+cells which resulted in reactivation of γ-globin expression [149,150,151].